Prostatic-specific antigen: An immunohistologic marker for prostatic neoplasms

Nadji, Mehrdad; Tabei, S. Z.; Castro, Albert; Chu, Tang–Yuan; Murphy, Gerald P.; Wang, Ming C.; Morales, Azorides R.

doi:10.1002/1097-0142(19810901)48:5<1229::aid-cncr2820480529>3.0.co;2-l

Cited by 335 publications

(93 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PSAP (prostate specific acid phosphatase) and PA (prostatic antigen) have been reported so far (Ablin, 1985;Nadji et al, 1981). It may be noted that antiserum to ILM does not show cross reactivity with acid phosphatase.…”

Section: Methodsmentioning

confidence: 79%

Studies on immunocytochemical localization of inhibin-like material in human prostatic tissue: Comparison of its distribution in normal, benign and malignant prostates

Doctor¹,

Sheth²,

Simha³

et al. 1986

Br J Cancer

View full text Add to dashboard Cite

Summary A specific antiserum has been generated against inhibin-like material (ILM) of prostatic origin. Using the immunoperoxidase technique, localization of ILM has been examined in a total of 114 prostates including normal (4 specimens), malignant (46) and hyperplastic (55) In the present study, we report immunocytochemical localization of inhibin-like material (ILM) in prostatic tissue. Inhibin is involved in the suppression of FSH synthesis and secretion. Of the various forms of inhibin-like materials (ILM) present in human seminal plasma, a peptide having a molecular weight of 10,400 daltons has been isolated in purified form from this laboratory (Thakur et al., 1981) the amino acid sequence of which has been reported (Sheth et al., 1984a; Johnson et al., 1984;Seidah et al., 1984). This peptide-ILM has been shown to be of prostatic origin (Sheth et al., 1984b;Beksac et al., 1984) and chemically similar (Johansson et al., 1984)

show abstract

Section: Methodsmentioning

confidence: 79%

Studies on immunocytochemical localization of inhibin-like material in human prostatic tissue: Comparison of its distribution in normal, benign and malignant prostates

Doctor¹,

Sheth²,

Simha³

et al. 1986

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…If doubt remained sections of the tumour were stained with a Prostatic Specific Antigen Immunohistology kit (HistoGeMTM) (Hadji et al, 1981).…”

Section: Methodsmentioning

confidence: 99%

The dedifferentiation of metastatic prostate carcinoma

Brawn

Speights²

1989

Br J Cancer

View full text Add to dashboard Cite

Summary Two hundred consecutive staging lymphadenectomies with metastatic prostate adenocarcinoma and 100 consecutive autopsies with widely disseminated metastatic prostate adenocarcinoma were identified. The metastases from 41% of the staging lymphadenectomies were entirely differentiated (gland forming) and an additional 43% were predominantly (50% or more) differentiated. In contrast, the metastases from 70% of the autopsies were entirely undifferentiated (non-gland forming) and an additional 18% were predominantly undifferentiated. Further, five patients with completely or predominantly differentiated metastases in staging lymphadenectomies were found to have widespread completely or predominantly undifferentiated metastases at autopsy 4-7 years later. These findings suggest that dedifferentiation occurs within metastases and that dedifferentiation within metastases may be important in understanding the widespread dissemination of metastatic prostate carcinoma.Dedifferentiation is characterised by a progression from a more differentiated to a less differentiated histological appearance with time. Dedifferentiation has been demonstrated experimentally and clinically within primary tumours but not, as yet, within metastases (Foulds, 1954;Kastendieck & Altenahr, 1976;Nowell, 1976;Brawn, 1983;Barnett & Eccles, 1984;Leonard & Smyth, 1985;Poste, 1986). In order to determine whether dedifferentiation occurs within metastases the current study compared the histology of metastatic prostate carcinoma in staging lymphadenectomies to the histology of widely disseminated prostate carcinoma at autopsy. Materials and methodsEight hundred and fifty-seven consecutive staging lymphadenectomies were performed on patients with a diagnosis of prostate carcinoma. Criteria for staging lymphadenectomy were: (1) confirmed histological diagnosis of prostate carcinoma in needle biopsy or transurethral resection of prostate; (2) prostate carcinoma clinically confined to the prostate, or 6cm or less in size if extending beyond the capsule of the prostate; and (3) no evidence of metastases preoperatively. Two hundred of these 857 staging lymphadenectomies had metastatic prostate carcinoma in pelvic lymph node(s) (obturator, hypogastric, external iliac, internal iliac or common iliac lymph nodes).One hundred consecutive autopsies with widely disseminated metastatic prostate carcinoma were identified. Widely disseminated metastatic prostate carcinoma was defined as metastases beyond lymph nodes and/or bone. Invasions from the prostate into adjacent tissue or organs were not considered to be metastases.Metastases were determined to be of prostatic origin by: (1) the histological appearance of the metastases; (2) a comparison of the histological appearance of the primary tumour and the metastases; (3) the gross description of the prostate; and (4) serum acid phosphatase levels. If doubt remained sections of the tumour were stained with a Prostatic Specific Antigen Immunohistology kit (HistoGeMTM) (Hadji et al., 1981).The current study examin...

show abstract

“…Immunohistochemical methods are used widely in order to identify specific cellular components and are applied routinely for staining of tissue PSA in order to identify cells of prostate origin (17,18). From such observations, lower levels of tissue PSA in high-grade tumors are well known (19,20).…”

Section: Discussionmentioning

confidence: 99%

“…In histopathology, immunostaining of tissue PSA has been used to identify cells of prostate origin (4,17,18). By qualitative or semiquantitative studies of tissue PSA, decreased tissue PSA levels were found in high-grade tumors (19,20).…”

mentioning

confidence: 99%